Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1612 1632 1638
This examiner grants 77% of resolved cases
Hanna Marie Thueson is an examiner in Tech Center 1600 and Art Unit 1600. The examiner has a 76.7% allowance rate across 30 resolved cases. The median days to allowance is 1284, which is a timeline for reaching a grant. While the case volume is 30, these figures offer a picture of the examiner's approach.
The interview lift is 28.2%, suggesting that interviews are a tool for this examiner. This lift provides a boost to the 76.7% baseline allowance rate. For practitioners, the 28.2% lift indicates that verbal communication can help resolve issues that might otherwise lead to abandonment. Given the 1284-day median pendency, an interview may also help move the case toward a grant. As the examiner's total of 30 resolved cases grows, these statistics will become more predictive. For now, they suggest an environment where interviews are beneficial for overcoming the challenges of Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19077772 | CELL DETACHMENT METHOD AND CELL DETACHMENT SYSTEM | Non-Final OA | CANON KABUSHIKI KAISHA |
| 18569550 | PRIMORDIAL GERM CELLS | Non-Final OA | The Regents of the University of California |
| 18354719 | METHOD FOR PRODUCING FOOD PRODUCTS USING CELLS GROWN IN CULTURE AS AN ALTERNATIVE TO ANIMAL HUSBANDRY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | Non-Final OA | The Regents of the University of California |
| 18074402 | ENGINEERED VASCULARIZED ORGANOIDS | Non-Final OA | The Regents of the University of California |
| 17770463 | PATIENT-MATCHED ORGANOID SYSTEMS FOR STUDYING CANCER | Non-Final OA | Massachusetts Institute of Technology |
| 17995114 | Kidney Organoids Having a Nephron-like Structure and Methods of Preparing the Same | Non-Final OA | POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION |
| 18040971 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR TREATMENT OF GRN-ASSOCIATED ADULT-ONSET NEURODEGENERATION | Final Rejection | The Trustees of the University of Pennsylvania |
| 18862323 | PATIENT-DERIVED CELL-CONTAINING DROPLETS ENABLE CLINICAL PRECISION ONCOLOGY | Non-Final OA | Duke University |
| 17620248 | INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | Non-Final OA | MESOBLAST INTERNATIONAL SÁRL |
| 18355798 | DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF | Final Rejection | CELLARTGEN INC. |
| 18347763 | ADIPOSE EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURING ORGANOID AND PREPARING METHOD THEREOF | Final Rejection | CELLARTGEN INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy